MEDICA GROUP PLC

Share Issue/Capital Change • Jul 30, 2021

National Storage Mechanism | Additional information

RNS Number : 9167G

Medica Group PLC

30 July 2021

Medica Group Plc

Issue of Equity and Total Voting Rights

Further to the Block Listing Application announcement on the 5 July 2021, Medica Group PLC (LSE:MGP, "Medica" or the "Company"), the UK and Ireland market leader in the provision of teleradiology services, has allotted and issued 36,477 of the 38,076 ordinary shares of 0.2 pence each in the capital of the Company ("New Ordinary Shares"). The New Ordinary Shares have been used to satisfy options under the Company's 2018 Sharesave Scheme. The New Ordinary Shares will rank pari passu with the Company's existing shares.

Following Admission of the New Ordinary Shares, the Company have 122,427,237 Ordinary Shares in issue. There are no Ordinary Shares held in treasury. Therefore, the Company hereby confirms that, following Admission of the New Ordinary Shares, the total number of voting rights in the Company are 122,427,237. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:  

Medica Group Plc: Dr. Stuart Quin, Chief Executive Officer Richard Jones, Chief Financial Officer	+44 (0)33 33 111 222
Investec Bank plc (Joint Broker) Sara Hale Daniel Adams Virginia Bull	+44 (0)20 7597 5970
Liberum (Joint Broker) Bidhi Bhoma Richard Lindley Euan Brown	+44 (0)20 3100 2000
FTI Consulting Victoria Foster Mitchell Sam Purewal	+44 (0)20 3727 1000

About Medica Group PLC

Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images. Medica also offers diabetic retinopathy screening in Ireland.

Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital and insurance groups, as well as diagnostic imaging companies. This enables the Company to offer a fast, responsive service. In addition, Medica operates in Australia and New Zealand through MedX, a 50:50 Joint Venture with Integral Diagnostics Limited Pty.

The Company currently offers two primary services to hospital radiology departments:

·    NightHawk - urgent reporting service

·    Elective - includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.

These services are underpinned by Medica's bespoke, secure IT platform that provides market-leading linkage between a hospital's Radiology Information System (RIS) and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report.

Through its subsidiary, RadMD, in the United States, Medica also provides pharmaceutical and biotech clients and contract research organisations (CROs) with high quality, complex imaging services for international clinical trials. RadMD has gained vast experience in the space, having contributed to over 500 international clinical trials, in all phases of clinical research from proof of concept to phase III and with expertise in oncology, as well as a wider range of therapeutic areas including medical devices, neurology and cardiovascular.

For more information please visit: www.medicagroupplc.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEKKLBLFDLZBBQ